TSLA
Tesla
-- 236.260 NVDA
NVIDIA
-- 118.530 PLTR
Palantir
-- 87.390 MU
Micron Technology
-- 103.000 INTC
Intel
-- 23.960 
NEWS
Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024
Autolus Therapeutics (NASDAQ: AUTL)presented clinical data updates at ASH 2024, featuring one oral and three poster presentations about obecabtagene autoleucel (obe-cel) for relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL).
The FELIX trial demonstrated that obe-cel treatment achieved deep molecular remission in 84% of responders, correlating with improved event-free survival and overall survival. The study showed that lower tumor burden at lymphodepletion yielded the best survival benefits.
Additional findings revealed that bridging therapies were effective with obe-cel, maintaining its expansion and persistence. The treatment showed low incidence of severe adverse events, potentially reducing healthcare resource utilization costs. A new CAR-HEMATOTOX risk score was identified as a useful tool for patient risk stratification.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment